DOCSLIB.ORG

Download Current Complete HIN Authorized Licensee List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Current Complete HIN Authorized Licensee List Health Industry Business Communications Council Health Industry Number System (HIN ®) Authorized Licensees Fresenius Kabi USA, Inc. The following companies (and/ Manufacturers Abbott Laboratories Fresenius Medical Care or their subsidiaries/divisions) AbbVie G1 Therapeutics, Inc. and organizations are authorized Acadia Pharmaceuticals GE Healthcare Genentech, Inc. licensees that have access to the Acrotech Biopharma LLC Akorn Pharmaceuticals Roche Labs Health Industry Number (HIN) Alexion Pharmaceuticals, Inc. Gilead Sciences, Inc. System Database, or a portion Alkermes Inc. Glaxo SmithKline, Inc. Glenmark Pharmaceuticals Inc. thereof. Allergan, Inc. Alvogen Inc Grifols USA, LLC Ambu Inc GyrusACMI dba Olympus-OSTA HIN licenses do not convey Amgen, Inc. Hikma Horizon Therapeutics USA, Inc. between a parent organization Amneal Pharmaceuticals, LLC Amphastar Pharmaceuticals, Inc. HPSRx Enterprises, Inc. and/or its subsidiaries and Apotex Corporation ICU Medical divisions. Each subsidiary and Argon Medical Devices, Inc. Incyte Ipsen Biopharmaceuticals Inc. division must maintain its own, Arjo Inc. Ascensia Diabetes Care Jazz Pharmaceuticals individual license to the HIN Astra Zeneca Johnson & Johnson Health Care Sys. Database in order to be an Aurobindo Pharma USA Advanced Sterilization Products Centocor Authorized Licensee AuroMedics Pharma LLC B. Braun Medical Inc. Cordis Corportion Bausch Health US, LLC. DuPuy Orthopaedics, Inc. Licensees have access to Bausch & Lomb Surgical Ethicon, Inc. Ethicon Endo Surgery, Inc. more than 1,000,000 customer Bavarian Nordic, Inc. Baxter Healthcare Corporation J&J Consumer Products location records and related Bayer Healthcare Pharmaceuticals J&J Merck Consumer Pharm. HIN assignments for use in Beckman Coulter, Inc. Janssen Pharma. Products, LP Lifescan, Inc. electronic commerce, customer Becton Dickinson Biogen Idec McNeil Consumer Healthcare Co. identification, and contract Blueprint Medicines (US) Ortho Biotech Products, LP administration. Boehringer Ingelheim Pharmaceuticals Ortho Clinical Diagnostics Bracco Diagnostics, Inc. Ortho McNeil Pharmacueticals Corp Bristol-Myers Squibb US Pharmaceuticals Scios, Inc. Last updated 9-10-2021 Celgene Corporation Therakos, Inc. CR Bard La Jolla Pharmaceutical Company CSL Behring Lannett Company Inc. Deciphera, Inc. Leadiant Biosciences, Inc. Dr. Reddy’s Laboratories Lundbeck LLC For more information, please Drugs Unlimited Inc. Luitpold Pharmaceuticals, Inc. contact the HIBCC office at: Dynavax Technologies Lupin Pharmaceuticals, Inc. Eisai, Inc. Mallinckrodt (Cadence) Pharmaceuticals, Inc. Mayne Pharma Inc 2525 E. Arizona Biltmore Circle Eli Lilly & Company EMD Serono, Inc Meitheal Pharmaceuticals Inc Suite 127 Endo Pharmaceuticals, Inc. Merck US Human Health Phoenix, AZ 85016 Epizyme, Inc. Millennium Pharmaceuticals TEL: 602.381.1091 EUSA Pharma (US) LLC Molnlycke Health Care US, LLC Exelixis, Inc. Mylan Institutional Inc. FAX: 602.381.1093 Mylan Pharmaceuticals [email protected] Ferring Pharmaceuticals Flexion Therapeutics Inc. Mylan Specialty LP (DeyPharma) www.hibcc.org HIN® Authorized Licensees Myovant Sciences, Inc. Cardinal Health SPD University Healthsystem Consortium Nestle Skin Health / Galderma Cesar Castillo, Inc. Voluntary Hospitals of America, Inc. Novartis Pharmaceuticals Corp. Dakota Drug, Inc. PedsPal / Cook Children’s Health Care Novo Nordisk Pharmaceuticals, Inc DDN Pharmaceuticals System Octapharma USA Inc Drogueria Betances, Inc. PracticeWell Oncopeptides, Inc. FFF Enterprises, Inc. Premier, Inc. Organon LLC Fresenius Medical Care UroGPO, LLC Pagadis, LLC General Injectables & Vaccines US Department of Defense DLA Troop Par Pharmaceutical Harvard Drug Group LLC dba Major Phar- Support Pfizer, Inc. maceutical Vizient Inc (Medassets) Pharmaceutical Associates, Inc. (PAI Health Coalition, Inc. Pharma) Hercules Pharmaceuticals, Inc Prasco Henry Schein Data Intermediaries Proctor & Gamble Personal Health Care Huntleigh Healthcare, Inc. Bell Canyon Consulting Purdue Pharma Independent Pharmacy Cooperative Blue Cross Blue Shield of South Carolina R & S Northeast LLC Kinray, Inc. Palmetto GBA Regeneron Pharmaceuticals Lifeline Pharmaceuticals LLC Chronicled Rising Pharmaceuticals Inc. McKesson Corporation Compile Inc Sagent Pharmaceuticals, Inc. McKesson Medical - Surgical Definitive Healthcare LLC Sanofi Aventis McKesson Pharmaceuticals Ernst & Young Sanofi Pasteur McKesson Specialty Care Solutions Eversana Life Science Services, LLC Vaxserve, Inc. Onmark, Inc. GardaWorld Federal Services Seattle Genetics, Inc. US Oncology Specialty LP IMS Health (Marketing Initiatives) Seqirus USA Inc. Medico-Mart, Inc. IMV Medical Information Division Shire US, Inc. Medline Industries Integrichain, Inc. Sobi, Inc. Metro Medical Supply, Inc. J. Knipper & Company Inc. Stryker Instruments Corp. Morris & Dickson Co. LLC Kalderos, Inc Sunovion Pharmacueticals, Inc. North Carolina Mutual Wholesale Drug Co. Lexis Nexis - Health Market Science, Inc. Taiho Oncology, Inc. Owens & Minor MedPro Systems Takeda Pharmaceuticals U.S.A., Inc. Parmed Pharmaceuticals Model N, Inc Tetraphase Pharmaceuticals LLC Priority Healthcare Corp. / Curascript Quintiles IMS America Teva Pharmaceuticals USA Quality Care Products Second Sight Solutions, a subsidiary of The Ritedose Corporation QK Healthcare, Inc Berkley Research Group Theravance Biopharma, Inc. Scripps Health Pharmaceutical Distrib. Saama Technologies, Inc. Tolmar Pharmaceuticals, Inc. Smith Drug Company Symphony Health Solutions Torrent Pharma Inc TerSera Therapeutics, LLC The Activus Group, LLC UCB Pharma, Inc. Tri-Anim Health Services, Inc. Tracelink Inc. Upsher-Smith Labs, Inc. Universal Hospital Services Truven Health Analytics Vertex Pharmacueticals, Inc. UPS Supply Chain Solutions VaxCare Corp WG Critical Care Value Drug Company Veeva Systems Inc. W L Gore & Associates, Inc. ZS Associates Wockhardt USA, LLC Zealand Pharma U.S., Inc. Zydus Pharmaceuticals Group Purchasing Organizations / Animal Health Database Animal Health Logistics Government Agencies Animalytix, LLC Afaxys Group Services LLC Wholesalers & Ceva Animal Health, LLC Amerinet (Intalere) Covetrus Inc Distributors Apexus, Inc. 3T Federal Solutions, LLC Ernst & Young Ascension Health Amerisource Corporation Harvard Drug Group Children’s Practicing Physicians (CPP) American Medical Distributors Heska Corporation Buying Group Amerisource Bergen MedPro Systems GastroGPO, LLC, a division of Specialty ASD Healthcare Patterson Veterinary Supply, Inc Networks, LLC Besse Medical Petsmart Inc HealthTrust Purchasing Group ICS - Integrated Commercial Solutions Royal Canin AdvantageTrust Oncology Supply Healix Infusion Therapy, LLC Anda, Inc. Innovatix Arbor Pharmaceuticals LLC Managed Health Care Associates, Inc. BHMS - A Cardinal Health Division Minnesota Multistate Contracting Alliance Capital Wholesale Drug Company New Source Ambulatory, LLC Cardinal Health, Inc Novation LLC Cardinal Health 3PL Specialty Solutions Provista Cardinal Health Med Products & Svcs.
Load more

Recommended publications
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 4
    DCAT MEMBER COMPANY MEETING LOCATOR v. 4 THE BENJAMIN Sancilio Pharmaceuticals Company, Inc. Sri Krishna Pharmaceuticals Ltd. Amino Chemicals Ltd. Zydus Pharmaceuticals (USA) Inc. Apogee Pharma, Inc. C2 PHARMA INTERCONTINENTAL BARCLAY Calyx Chemicals & Pharmaceuticals Ltd. AbbVie* ChemCon GmbH ACIC Pharmaceuticals Inc. Concord Biotech Limited Advitech SA Dipharma Francis Srl Amneal Pharmaceuticals LLC DSM Sinochem Pharmaceuticals ALP Pharm F.I.S. - Fabbrica Italiana Sintetici S.p.A. AMRI Jost Chemical Co. Asymchem Inc. Jubilant Pharma Capsugel, Now a Lonza Company* PharmSource, A GlobalData Company CBC AMERICAS Corp. PolyPeptide Group CellMark USA, LLC ROHNER Inc. Charioteer Pharmaceutical Co., Ltd., Zhejiang FIFTY NYC, A AFFINA HOTEL Chemical and Pharmaceutical Solutions Chiral Quest Corp. Chartwell Pharmaceuticals, LLC Croda, Inc. HOTEL 48LEX DFE Pharma AB BioTechnologies, Inc. DPL-US AiPing Pharmaceutical, Inc. EQ Esteve Almac Evonik Corporation Aptuit LLC FAREVA SA AZAD Fine Chemicals Ltd. Flavine North America, Inc. Cambridge Isotope Laboratories, Inc. Formosa Laboratories, Inc. CMC Biologics Grifols International S.A. Groupe Parima Hainan Poly Pharm. Co., Ltd. Navin Fluorine International Limited Harris Pharmaceutical Qualicaps, Inc. Helm AG RC2 Pharma Connect LLC Hetero USA, Inc. Recipharm Hikal, Ltd. Recro Gainesville LLC Interchem Corporation Reed-Lane, Inc. Inventia Healthcare PVT LTD Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D PiSA BioPharm, Inc. SPI Pharma Inc. Johnson Matthey Tapemark Kingchem Life Science LLC Unither Pharmaceutical Legacy Pharmaceutical Packaging Uquifa S.A. Lonza AG* Neuland Laboratories Ltd. LOTTE NY PALACE Orion Group AbbVie* Par Pharmaceutical, Inc.
    [Show full text]
  • BTG INTERNATIONAL LIMITED V. AMNEAL PHARMACEUTICALS LLC
    United States Court of Appeals for the Federal Circuit ______________________ BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., WOCKHARDT BIO AG, WOCKHARDT USA LLC, WOCKHARDT LTD., MYLAN PHARMACEUTICALS INC., MYLAN INC., WEST-WARD PHARMACEUTICALS CORP., NKA HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS LLC, TEVA PHARMACEUTICALS USA, INC., Defendants-Appellees PAR PHARMACEUTICAL, INC., PAR PHARMACEUTICAL COMPANIES, INC., RISING PHARMACEUTICALS, INC., Defendants ______________________ 2019-1147 ______________________ Appeal from the United States District Court for the District of New Jersey in Nos. 2:15-cv-05909-KM-JBC, 2:16-cv-02449-KM-JBC, 2:17-cv-06435-KM-JBC, Judge Kevin McNulty. 2 BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMERIGEN PHARMACEUTICALS, INC., AMERIGEN PHARMACEUTICALS LIMITED, Defendants-Appellees ______________________ 2019-1148 ______________________ Appeal from the United States District Court for the District of New Jersey in No. 2:16-cv-02449-KM-JBC, Judge Kevin McNulty. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - JANSSEN
    [Show full text]
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
    [Show full text]
  • HEALTH BENEFITS Providing Value for Our Employees
    HEALTH BENEFITS Providing Value for Our Employees March 2017 Business Roundtable CEO members lead companies with more than $6 trillion in annual revenues and nearly 15 million employees. The combined market capitalization of Business Roundtable member companies is the equivalent of nearly one-quarter of total U.S. stock market capitalization, and Business Roundtable members invest $103 billion annually in research and development — equal to 30 percent of U.S. private R&D spending. Our companies pay $226 billion in dividends to shareholders and generate $412 billion in revenues for small and medium-sized businesses annually. Business Roundtable companies also make more than $7 billion a year in charitable contributions. Please visit us at www.brt.org, check us out on Facebook and LinkedIn, and follow us on Twitter. Copyright © 2017 by Business Roundtable HEALTH BENEFITS Providing Value for Our Employees March 2017 March 2017 DEAR BUSINESS LEADERS AND STAKEHOLDERS: I am pleased to share with you a new report highlighting what leading U.S. companies are doing to improve health outcomes for our employees and their families. America’s employer-sponsored health benefits system is the foundation of health care in the United States. Of the 209 million Americans who are covered by health insurance plans, 85 percent — or 177 million Americans* — receive health coverage through an employer. This report demonstrates many different ways employers are helping to drive a health care system that delivers better health care quality and value. I hope you find this report helpful. Sincerely, Brian Moynihan Chairman and Chief Executive Officer Bank of America * Bureau of Labor Statistics, Health Insurance Coverage in the United States: 2015, Current Population Reports, September 2016.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Fidelity® Select Portfolio® Pharmaceuticals Portfolio
    Quarterly Holdings Report for Fidelity® Select Portfolio® Pharmaceuticals Portfolio November 30, 2020 PHR-QTLY-0121 1.810707.116 Schedule of Investments November 30, 2020 (Unaudited) Showing Percentage of Net Assets Common Stocks – 98.3% Shares Value Shares Value Biotechnology – 17.6% Bausch Health Cos., Inc. (Canada) (a) 535,300 $ 9,937,694 Biotechnology – 17.6% Bristol‑Myers Squibb Co. 1,295,680 80,850,432 Acceleron Pharma, Inc. (a) 128,800 $ 15,207,416 Catalent, Inc. (a) 75,400 7,248,956 Amgen, Inc. 137,400 30,508,296 Elanco Animal Health, Inc. (a) 172,400 5,273,716 Argenx SE (a) 17,400 4,983,924 Eli Lilly & Co. 416,961 60,730,370 Ascendis Pharma A/S sponsored ADR (a) 51,300 8,655,849 GlaxoSmithKline PLC sponsored ADR 348,300 12,813,957 Atea Pharmaceuticals, Inc. 39,800 1,326,136 Harmony Biosciences Holdings, Inc. 133,077 5,467,801 Athenex, Inc. (a) (b) 166,800 2,273,484 Horizon Therapeutics PLC (a) 316,100 22,262,923 BioNTech SE ADR (a) (b) 50,148 6,230,388 Intra‑Cellular Therapies, Inc. (a) 107,000 2,529,480 Blueprint Medicines Corp. (a) 80,300 8,678,824 Johnson & Johnson 337,850 48,880,138 ChemoCentryx, Inc. (a) 6,400 352,960 Merck & Co., Inc. 515,936 41,476,095 Galapagos Genomics NV sponsored ADR (a) 36,900 4,524,309 Nektar Therapeutics (a) (b) 368,233 6,035,339 Generation Bio Co. (b) 16,738 807,106 Novartis AG sponsored ADR 441,496 40,101,082 Generation Bio Co.
    [Show full text]
  • Case 5:19-Cv-01087-OLG Document 55 Filed 05/07/20 Page 1 of 11
    Case 5:19-cv-01087-OLG Document 55 Filed 05/07/20 Page 1 of 11 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS SAN ANTONIO DIVISION RAMON D. JOHNSON, II, § Plaintiffs, § § v. § § Civil Action No. 5:19-cv-01087-OLG NOVARTIS PHARMACEUTICALS § CORPORATION; TARO § PHARMACEUTICALS USA, INC.; § BAUSCH HEALTH US, LLC; SUN § PHARMACEUTICAL INDUSTRIES § LTD.; and TORRENT PHARMA, INC., § Defendants. § ORDER On this day, the Court considered the status of the above-captioned case. Currently pending before the Court are Defendants Sun Pharmaceutical Industries and Tara Pharmaceuticals USA’s Motion to Dismiss (docket no. 8); Defendant Novartis Pharmaceuticals Corporation’s Motion to Dismiss (docket no. 9); Defendant Torrent Pharma, Inc.’s Motion to Dismiss (docket no. 12); and Defendant Bausch Health US, LLC’s Motion to Dismiss (docket no. 23). Also pending are Plaintiff’s Motion for Leave to File a Combined Rebuttal to Defendants’ Replies in Support of their Motions to Dismiss (docket no. 44) and Plaintiff’s Motion for Leave to File a First Amended Complaint for a Civil Case and To Edit the Style of the Case (docket no. 47). Having considered each of these Motions and the record, the Court finds that Defendants’ Motions to Dismiss should be GRANTED. BACKGROUND On September 10, 2019, Plaintiff Ramon D. Johnson II (“Plaintiff”) initiated this lawsuit alleging that he suffered personal injuries resulting from his use of two drugs: Minocycline and Carbamazepine. See docket no. 1. Specifically, Plaintiff alleges that he was prescribed 1 Case 5:19-cv-01087-OLG Document 55 Filed 05/07/20 Page 2 of 11 Minocycline in April 2013 for an unrelated condition.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Mckesson CORPORATION
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ‘ Filed by a Party other than the Registrant Check the appropriate box: ‘ Preliminary Proxy Statement ‘ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) Definitive Proxy Statement ‘ Definitive Additional Materials ‘ Soliciting Material Pursuant to §240.14a-12 McKESSON CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. ‘ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ‘ Fee paid previously with preliminary materials. ‘ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: A LETTER FROM OUR INDEPENDENT CHAIR Dear Fellow Shareholders, First and foremost, on behalf of the Board of Directors, I would like to thank you for your investment in McKesson and for the confidence you place in this Board to oversee your interests in our Company particularly through the most unprecedented global health crisis in modern history.
    [Show full text]